POINT: Should All Patients With Idiopathic Pulmonary Fibrosis, Even Those With More Than Moderate Impairment, Be Treated With Nintedanib or Pirfenidone? Yes
نویسندگان
چکیده
منابع مشابه
Pirfenidone should be prescribed for patients with idiopathic pulmonary fibrosis.
Pirfenidone works. There have been four randomised placebo-control trials of pirfenidone for the treatment of idiopathic pulmonary fibrosis (IPF); a phase II and phase III study in Japan, and two international multicentre phase III studies. In all four studies, patients treated with pirfenidone had slower rates of decline in lung volume (vital capacity (VC) in the Japanese studies and forced vi...
متن کاملWhether all patients with Central precocious puberty should be treated?
Extended Abstract Precocious puberty is the appearance of secondary sexual characteristics before 8 years old in girls and 9 years old in boys. Precocious puberty is divided into 3 groups of central, peripheral and normal variants. Central precocious puberty is accompanied by activation of hypothalamic-pituitary-gonadal axis which causes increase in secretion of GnRH, and in turn increase i...
متن کاملI-17: Should All Women with PCOS-Related Infertility Be Treated with Insulin Sensitizing Drugs?
Interest in the role of insulin sensitizing drugs (ISDs) as a means of reducing compensatory hyperinsulinemia in the hope of improving metabolic and reproductive functions in women with PCOS has grown measurably over the past decade. Metformin is believed to lower fasting serum insulin levels in insulin-resistance. For the management of ovulatory infertility in the nonobese PCOS population (BMI...
متن کاملClinical use of nintedanib in patients with idiopathic pulmonary fibrosis
Idiopathic pulmonary fibrosis (IPF) is a rare lung disease characterised by progressive loss of lung function, dyspnoea and cough. IPF has a variable clinical course but a poor prognosis. Nintedanib, a tyrosine kinase inhibitor, is one of two drugs approved for the treatment of IPF. In clinical trials, nintedanib slowed disease progression by reducing the rate of decline in forced vital capacit...
متن کاملClinical use of nintedanib in patients with idiopathic pulmonary fibrosis
Hajari Case A, Johnson P. BMJ Open Resp Res 2017;4:e000192. doi:10.1136/bmjresp-2017-000192 AbstrAct Idiopathic pulmonary fibrosis (IPF) is a rare lung disease characterised by progressive loss of lung function, dyspnoea and cough. IPF has a variable clinical course but a poor prognosis. Nintedanib, a tyrosine kinase inhibitor, is one of two drugs approved for the treatment of IPF. In clinical ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Chest
سال: 2016
ISSN: 0012-3692
DOI: 10.1016/j.chest.2016.04.034